Shanghai Medicilon (SHSE:688202) Total Liabilities : ¥596.3 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Total Liabilities?

Shanghai Medicilon's Total Liabilities for the quarter that ended in Sep. 2024 was ¥596.3 Mil.

Shanghai Medicilon's quarterly Total Liabilities declined from Mar. 2024 (¥656.48 Mil) to Jun. 2024 (¥548.98 Mil) but then increased from Jun. 2024 (¥548.98 Mil) to Sep. 2024 (¥596.33 Mil).

Shanghai Medicilon's annual Total Liabilities increased from Dec. 2021 (¥466.06 Mil) to Dec. 2022 (¥726.80 Mil) and increased from Dec. 2022 (¥726.80 Mil) to Dec. 2023 (¥755.07 Mil).

Shanghai Medicilon Total Liabilities Historical Data

The historical data trend for Shanghai Medicilon's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Total Liabilities Chart

Shanghai Medicilon Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

127.73

279.16

466.06

726.80

755.07

Shanghai Medicilon Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															880.21	755.07	656.48	548.98	596.33

Shanghai Medicilon Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Medicilon's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	686.36	+	(14.28	+	54.428
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	755.1

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3265.847	-	2510.779
	=	755.1

Shanghai Medicilon's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	540.082	+	(11.187	+	45.057
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	596.3

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	2948.181	-	2351.855
	=	596.3

Shanghai Medicilon Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Medicilon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299

Website

http://www.medicilon.com.cn

Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Executives

Chen Jin Zhang	Director
Chen Guo Xing	Director
Lin Zhang Qing	Director
Peng Shuang Qing	Core technical personnel
Li Zhi Gang	Core technical personnel
Xu Yong Mei	Core technical personnel
Liu Bin Bin	senior management
Zhang Xiao Dong	senior management
Xue Chao	senior management
Ma Xing Quan	senior management
	Directors, senior managers, core technical personn
Cai Jin Na	Directors, senior managers

Shanghai Medicilon Headlines

No Headlines